Related Experiment Video
Updated: Dec 30, 2025
10:16
High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
Published on: October 30, 2021
4.1K
Small Molecule Inhibitors Targeting Chikungunya Virus
Nicole Haese1, John Powers1, Daniel N Streblow2
1Vaccine and Gene, Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, 505 NW 185th Avenue, 97006, Beaverton, OR, USA.
Current Topics in Microbiology and Immunology
|January 25, 2020
Summary
Chikungunya virus (CHIKV) infection causes chronic pain and has no approved treatments. This review explores small molecule inhibitors as a potential therapeutic strategy against CHIKV.
Area of Science:
- Virology
- Immunology
- Drug Discovery
Background:
- Chikungunya virus (CHIKV) infection leads to debilitating chronic joint and muscle pain.
- Viral persistence contributes to the long-term symptoms of CHIKV disease.
- Current treatments for CHIKV focus on symptom management, not viral load reduction.
Purpose of the Study:
- To review the development of small molecule inhibitors against CHIKV.
- To highlight the need for novel therapeutics targeting CHIKV replication.
- To discuss strategies for overcoming CHIKV mutations with multi-targeted therapies.
Main Methods:
- Literature review of small molecule inhibitor development for CHIKV.
- Analysis of CHIKV replication cycle and mutation potential.
- Summary of current therapeutic strategies and challenges.
Main Results:
- Small molecule inhibitors show promise in targeting CHIKV replication.
- No approved vaccines or therapeutics currently exist for established CHIKV infections.
- CHIKV's rapid mutation necessitates multi-targeted therapeutic approaches.
Conclusions:
- Small molecule inhibitors represent a promising avenue for CHIKV treatment development.
- Targeting multiple aspects of the CHIKV replication cycle is crucial.
- Further research into novel therapeutics is essential to improve patient outcomes for CHIKV disease.
